Understanding Pharmacogenomics And Safer Medicines
Medicines can produce very different effects in people who receive the same dose. Age, kidney and liver function, other treatments, diet, illness, and adherence all influence response. Genetics is another important factor: inherited differences can affect how quickly a person processes a medicine, how strongly a target responds, or whether a harmful metabolite accumulates.
Pharmacogenomics applies genomic information to medication decisions. It can help clinicians select a suitable medicine, adjust a dose, or identify treatments that may carry an avoidable risk for a particular patient. Its purpose is not to replace clinical judgement, but to make prescribing more precise and reduce preventable adverse drug reactions.
For a health translation network such as the Brisbane Diamantina network, this field connects laboratory discovery with practical improvements in prescribing, patient safety, research, education, and service design. The value emerges when a validated genetic test can be used reliably in everyday care.
Why Adverse Drug Reactions Happen
An adverse drug reaction is a harmful or unintended response to a medicine used at an appropriate dose. Some reactions are predictable from the drug’s pharmacology, while others arise from unusual sensitivity, immune responses, interactions, or differences in drug metabolism. A reaction may be mild, such as nausea, or severe, including bleeding, organ injury, respiratory problems, or a life-threatening skin reaction.
Genetic variation can influence enzymes, transport proteins, and drug receptors. For example, a person who metabolises a medicine slowly may develop excessive exposure at a standard dose. Someone who metabolises it rapidly may receive too little therapeutic benefit. In other cases, a genetic marker can indicate a higher risk of an immune-mediated response, even when the medicine is otherwise appropriate.
Pharmacogenomics therefore adds a layer of individualised risk assessment. It works alongside a medication history, allergies, pathology results, comorbidities, and clinical monitoring rather than acting as an isolated prediction tool.
How Genetic Information Guides Prescribing
Pharmacogenomic testing usually examines specific variants with established associations to a medicine or drug class. Results may classify a patient as a normal, intermediate, poor, or ultrarapid metaboliser. Clinical guidance can then recommend a standard dose, a modified dose, closer monitoring, or an alternative treatment.
The approach is especially relevant when a medicine has a narrow therapeutic index, serious dose-related toxicity, or substantial variation in treatment response. It may also be useful when a patient has experienced an unexplained reaction, failed several medicines, or needs a long-term treatment where early optimisation could prevent harm.
A result is not a guarantee that a reaction will or will not occur. Genetics may explain part of the risk, but environmental exposures, infections, concurrent medicines, and changes in health can alter the outcome. Responsible interpretation requires current evidence and a clinician who can place the result in context.
From Genomic Evidence To Clinical Care
Moving pharmacogenomics into routine practice involves several stages. Researchers must establish a credible gene–medicine association, laboratories must provide accurate testing, and health services must create workflows for ordering, reporting, recording, and acting on results. Patients also need clear information about what the test can reveal and what it cannot predict.
Implementation is a shared task across pharmacists, doctors, nurses, genetic counsellors, laboratory specialists, researchers, information technology teams, and consumers. Electronic prescribing systems may provide alerts or dose guidance, but those prompts must be clinically relevant. Excessive alerts can cause fatigue, while missing or poorly timed information can limit the benefit of testing.
Health translation also requires attention to equity. Testing should be accessible to people from diverse communities, and evidence should represent the populations receiving care. Consent, privacy, data security, and the governance of genomic information are essential parts of a trustworthy service.
| Clinical decision point | Possible pharmacogenomic contribution | What still matters |
|---|---|---|
| Starting a medicine | Identify a safer option or initial dose | Diagnosis, treatment goals, allergies, and current medicines |
| Adjusting treatment | Explain unusual response or toxicity | Symptoms, pathology, adherence, and clinical examination |
| Reviewing long-term therapy | Support a more suitable medicine | New illnesses, ageing, organ function, and interactions |
| Responding to a serious reaction | Clarify inherited susceptibility | Immediate treatment, specialist review, and accurate documentation |
Examples Across Different Areas Of Care
Pharmacogenomic guidance is already relevant to several commonly prescribed medicines. Variants affecting drug-metabolising enzymes can influence the response to selected antidepressants, pain medicines, cardiovascular treatments, and therapies used in cancer care. Other markers are associated with severe reactions to particular medicines in people with specific genetic backgrounds.
In oncology, genomic information can support both tumour-directed treatment and safer use of supportive medicines. In mental health care, metabolism differences may help explain why a patient experiences adverse effects or limited benefit, although prescribing decisions still depend on symptoms, preferences, psychological care, and follow-up.
The same principle applies in chronic disease management, where patients may take several medicines for years. A more informed initial choice can reduce trial-and-error prescribing, but the test should be ordered when it is likely to change management. Broad testing without a clear clinical pathway can create uncertain findings and unnecessary expense.
Making Results Useful For Patients
A pharmacogenomic result should be communicated in plain language. Patients need to know whether the finding affects a current medicine, whether an alternative is available, and whether the information may be useful in the future. Results should be stored in a durable, accessible record so they are not lost when a person changes doctors, hospitals, or pharmacies.
Medication reconciliation is particularly important. A genetic result may be relevant when a new prescription is written, during hospital admission, or after discharge. Pharmacists can help identify interactions and ensure that the documented recommendation matches the medicine and dose actually supplied.
Education for health professionals is equally important. Clinicians do not need to become genomic scientists, but they should understand test limitations, evidence strength, result terminology, and when to seek specialist advice. Resources that translate research into practical care pathways can make adoption safer and more consistent.
Building A Safer Translation Pathway
Successful programs measure outcomes rather than simply counting tests. Useful measures may include preventable adverse drug reactions, treatment response, hospital admissions, time to effective therapy, patient understanding, and the consistency of prescribing decisions. Economic evaluation can show whether testing provides value in a particular population or service.
Research partnerships can identify where pharmacogenomics is most likely to improve care in Queensland communities. Lessons from other clinical translation projects are valuable too; for example, the fall prevention guide demonstrates how evidence can be shaped into an intervention that fits real-world health services.
Practical priorities for organisations developing or expanding a pharmacogenomic service include:
- Select medicines and patient groups with strong evidence and a clear clinical action.
- Establish consent, privacy, laboratory quality, and genomic data governance processes.
- Integrate results into prescribing and electronic health record workflows.
- Train clinicians and pharmacists to interpret results consistently.
- Evaluate patient outcomes, equity, costs, and unintended effects over time.
Pharmacogenomics offers a measured way to reduce medication-related harm by recognising that patients do not respond identically to the same treatment. Its greatest impact will come from collaboration between researchers, health services, clinicians, patients, and communities. Health organisations can begin by identifying high-risk prescribing situations, reviewing available evidence, and developing a monitored pathway that turns a genetic result into a clear, safe clinical action.
